CTOs on the Move

Allied Digestive Health

www.allieddigestivehealth.com

 
Allied Digestive Health is an integrated network of gastroenterology Care Centers. Our multi-specialty group is a dedicated, compassionate team...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Mental Health Partners

Mental Health Partners is Boulder and Broomfield Counties behavioral health center. Proudly serving our community for over 50 years. Get in. Get help. Get Better.

Clinical Match

Clinical Match™ is a physician-founded community of clinical investigators, patients, volunteers, and providers working towards the advancement of medicine.

Ray America

Since its establishment in 2004, Ray has been leading the global market in digital dentistry by proposing a new standard for dental imaging solutions through state-of-the-art technology.

Cambridge Major Laboratories

Cambridge Major Laboratories is a leading global chemistry outsourcing partner to the pharmaceutical and biotechnology industries

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.